View in EDS

Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer.

Saved in:
Bibliographic Details
Title: Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer.
Authors: Bocobo A; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA., Whitman J; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA., Keenan BP; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Division of Hematology and Oncology, Department of Medicine, San Francisco, CA; UCSF HDFCCC Cancer Immunotherapy Program, San Francisco, CA., Koser KL; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA., Kidder WA; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Division of Hematology and Oncology, Department of Medicine, San Francisco, CA., Piawah S; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Division of Hematology and Oncology, Department of Medicine, San Francisco, CA., Van Loon K; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Division of Hematology and Oncology, Department of Medicine, San Francisco, CA., Behr SC; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA., Kolli KP; UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA., Chen X; UCSF Clinical Cancer Genomic Laboratory, San Francisco, CA., Onodera C; UCSF Clinical Cancer Genomic Laboratory, San Francisco, CA., Pande M; UCSF Clinical Cancer Genomic Laboratory, San Francisco, CA., Pollak M; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA., Wang R; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA., Babdor J; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA; UCSF Department of Otolaryngology - Head and Neck Surgery and Department of Microbiology & Immunology, San Francisco, CA., Spitzer MH; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Department of Otolaryngology - Head and Neck Surgery and Department of Microbiology & Immunology, San Francisco, CA., Zhang L; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Division of Hematology and Oncology, Department of Medicine, San Francisco, CA; UCSF Department of Epidemiology and Biostatistics, San Francisco, CA., Fong L; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Division of Hematology and Oncology, Department of Medicine, San Francisco, CA; UCSF HDFCCC Cancer Immunotherapy Program, San Francisco, CA., Atreya CE; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Division of Hematology and Oncology, Department of Medicine, San Francisco, CA; UCSF HDFCCC Cancer Immunotherapy Program, San Francisco, CA. Electronic address: chloe.atreya@ucsf.edu.
Source: Clinical colorectal cancer [Clin Colorectal Cancer] 2026 Jun; Vol. 25 (2), pp. 271-282. Date of Electronic Publication: 2026 Feb 18.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101120693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0674 (Electronic) Linking ISSN: 15330028 NLM ISO Abbreviation: Clin Colorectal Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41826077
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Bocobo+A%22">Bocobo A</searchLink>; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Whitman+J%22">Whitman J</searchLink>; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Keenan+BP%22">Keenan BP</searchLink>; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Division of Hematology and Oncology, Department of Medicine, San Francisco, CA; UCSF HDFCCC Cancer Immunotherapy Program, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Koser+KL%22">Koser KL</searchLink>; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Kidder+WA%22">Kidder WA</searchLink>; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Division of Hematology and Oncology, Department of Medicine, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Piawah+S%22">Piawah S</searchLink>; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Division of Hematology and Oncology, Department of Medicine, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Van+Loon+K%22">Van Loon K</searchLink>; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Division of Hematology and Oncology, Department of Medicine, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Behr+SC%22">Behr SC</searchLink>; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Kolli+KP%22">Kolli KP</searchLink>; UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Chen+X%22">Chen X</searchLink>; UCSF Clinical Cancer Genomic Laboratory, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Onodera+C%22">Onodera C</searchLink>; UCSF Clinical Cancer Genomic Laboratory, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Pande+M%22">Pande M</searchLink>; UCSF Clinical Cancer Genomic Laboratory, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Pollak+M%22">Pollak M</searchLink>; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Wang+R%22">Wang R</searchLink>; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Babdor+J%22">Babdor J</searchLink>; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA; UCSF Department of Otolaryngology - Head and Neck Surgery and Department of Microbiology & Immunology, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Spitzer+MH%22">Spitzer MH</searchLink>; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Department of Otolaryngology - Head and Neck Surgery and Department of Microbiology & Immunology, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Zhang+L%22">Zhang L</searchLink>; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Division of Hematology and Oncology, Department of Medicine, San Francisco, CA; UCSF Department of Epidemiology and Biostatistics, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Fong+L%22">Fong L</searchLink>; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Division of Hematology and Oncology, Department of Medicine, San Francisco, CA; UCSF HDFCCC Cancer Immunotherapy Program, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Atreya+CE%22">Atreya CE</searchLink>; University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, CA; UCSF Division of Hematology and Oncology, Department of Medicine, San Francisco, CA; UCSF HDFCCC Cancer Immunotherapy Program, San Francisco, CA. Electronic address: chloe.atreya@ucsf.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101120693%22">Clinical colorectal cancer</searchLink> [Clin Colorectal Cancer] 2026 Jun; Vol. 25 (2), pp. 271-282. <i>Date of Electronic Publication: </i>2026 Feb 18.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101120693 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1938-0674 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215330028%22">15330028 </searchLink><i>NLM ISO Abbreviation: </i>Clin Colorectal Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41826077
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.clcc.2026.02.003
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 271
    Titles:
      – TitleFull: Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bocobo A
      – PersonEntity:
          Name:
            NameFull: Whitman J
      – PersonEntity:
          Name:
            NameFull: Keenan BP
      – PersonEntity:
          Name:
            NameFull: Koser KL
      – PersonEntity:
          Name:
            NameFull: Kidder WA
      – PersonEntity:
          Name:
            NameFull: Piawah S
      – PersonEntity:
          Name:
            NameFull: Van Loon K
      – PersonEntity:
          Name:
            NameFull: Behr SC
      – PersonEntity:
          Name:
            NameFull: Kolli KP
      – PersonEntity:
          Name:
            NameFull: Chen X
      – PersonEntity:
          Name:
            NameFull: Onodera C
      – PersonEntity:
          Name:
            NameFull: Pande M
      – PersonEntity:
          Name:
            NameFull: Pollak M
      – PersonEntity:
          Name:
            NameFull: Wang R
      – PersonEntity:
          Name:
            NameFull: Babdor J
      – PersonEntity:
          Name:
            NameFull: Spitzer MH
      – PersonEntity:
          Name:
            NameFull: Zhang L
      – PersonEntity:
          Name:
            NameFull: Fong L
      – PersonEntity:
          Name:
            NameFull: Atreya CE
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2026 Jun
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1938-0674
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Clinical colorectal cancer
              Type: main
ResultId 1